Spotlight on anagrelide hydrochloride for the treatment of essential thrombocythemia

php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Orphan Drugs: Research and Reviews 2017:7 11–23 Orphan Drugs: Research and Reviews Dovepress

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  2017-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/ODRR.S93451
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Equivalence of BCSH and WHO diagnostic criteria for ET

  2017influential reference
• The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

  2016cited by this paper
• Closing the gap: genetic landscape of MPN.

  2016cited by this paper
• Long‐term follow‐up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status

  2016cited by this paper
• Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.

  2016cited by this paper
• Anagrelide and Mutational Status in Essential Thrombocythemia

  2016cited by this paper
• How we diagnose and treat essential thrombocythaemia

  2015cited by this paper
• Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study.

  2015cited by this paper
• Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.

  2015cited by this paper
• Myeloproliferative Neoplasms: A Contemporary Review.

  2015cited by this paper
• WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect – the Danish experience

  2015cited by this paper
• Anagrelide platelet‐lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms

  2015cited by this paper
• Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

  2015cited by this paper
• Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

  2015cited by this paper
• The importance of calcium in the regulation of megakaryocyte function

  2014cited by this paper
• Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca2+: some mechanistic and therapeutic implications

  2014cited by this paper
• Treatment of Essential Thrombocythemia in Europe: An Observational Study of 3649 High-Risk Patients in Exels

  2014cited by this paper
• Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia

  2014cited by this paper
• Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid® efficacy and long-term safety study

  2014influential reference
• Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

  2013influential reference
• Somatic mutations of calreticulin in myeloproliferative neoplasms.

  2013influential reference
• Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

  2013cited by this paper
• Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

  2013cited by this paper
• Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study.

  2013cited by this paper
• Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

  2013cited by this paper
• Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

  2013influential reference
• Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study

  2012cited by this paper
• Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.

  2012cited by this paper
• Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort.

  2012influential reference
• Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia

  2011cited by this paper
• Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.

  2011cited by this paper
• Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria.

  2010cited by this paper
• Guideline for investigation and management of adults and children presenting with a thrombocytosis

  2010cited by this paper
• Anagrelide represses GATA‐1 and FOG‐1 expression without interfering with thrombopoietin receptor signal transduction

  2010cited by this paper
• Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.

  2009cited by this paper
• Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.

  2009cited by this paper
• JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

  2009cited by this paper
• Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

  2008cited by this paper
• Anagrelide treatment in myeloproliferative disorders.

  2006cited by this paper
• Anagrelide: What Was New in 2004 and 2005?

  2006influential reference
• When and how to treat essential thrombocythemia.

  2005cited by this paper
• Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.

  2005cited by this paper
• Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• Treatment of symptomatic patients with essential thrombocythemia: Effectiveness of anagrelide

  2005cited by this paper
• Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures

  2005influential reference
• Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

  2005influential reference
• Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

  2004cited by this paper
• Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.

  2004cited by this paper
• Anagrelide for thrombocytosis in myeloproliferative disorders

  2004cited by this paper
• Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.

  2003cited by this paper
• Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells

  2003influential reference
• Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea

  2002influential reference
• Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.

  2002cited by this paper
• Long-term use of anagrelide in young patients with essential thrombocythemia.

  2001cited by this paper
• Platelets, leukocytes, and coagulation

  2001cited by this paper
• Anagrelide: a novel agent for the treatment of myeloproliferative disorders

  2000cited by this paper
• Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia.

  1999cited by this paper
• Calreticulin: one protein, one gene, many functions.

  1999cited by this paper
• Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany

  1998cited by this paper
• Anagrelide, a selective thrombocytopenic agent.

  1998cited by this paper
• Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.

  1997cited by this paper
• Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.

  1997cited by this paper
• Anagrelide as a New Platelet-Lowering Agent in Essential Thrombocythemia: Mechanism of Action, Efficacy, Toxicity, Current Indications

  1997cited by this paper
• Measurements of In Vivo Megakaryocytopoiesis: Studies in Nonhuman Primates and Patients

  1996cited by this paper
• Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

  1995cited by this paper
• Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.

  1992cited by this paper
• Inhibition of Platelet Production Induced by an Antiplatelet Drug, Anagrelide, in Normal Volunteers

  1984cited by this paper
• Disposition of anagrelide, an inhibitor of platelet aggregation

  1981cited by this paper
• Correlation with

  year unknowncited by this paper

• Bioequivalence and Pharmacokinetics of Low-Dose Anagrelide 0.5 mg Capsules in Healthy Volunteers

  2025influential citation
• Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group

  2023cites this paper
• Management of Myeloproliferative Neoplasms (MPNs)

  2022influential citation
• Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.

  2022cites this paper
• Anagrelide is an anti-megakaryocytic and not an anti-platelet agent

  2018cites this paper